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Abstract
Introduction: Takayasu arteritis (TA) is an idiopathic large-vessel vasculitis affecting the aorta and its major
branches. Although the disease rarely affects children, it does occur, even in infants. The objective of this study was
to evaluate the clinical features, disease activity, treatment and outcome of childhood TA in a tertiary UK centre.
Methods: We analysed a retrospective case series of children fulfilling the TA classification criteria of the European
League against Rheumatism, the Paediatric Rheumatology European Society and the Paediatric Rheumatology
International Trials Organisation. Data regarding demographics, clinical features, treatments and outcomes were
recorded. Descriptive statistics are expressed as median and range. Fisher’s exact test was used for group
comparisons. The Paediatric Vasculitis Activity Score (PVAS), Paediatric Vasculitis Damage Index (PVDI), Disease
Extent Index-Takayasu (DEI.Tak) and Indian Takayasu Arteritis Activity Score (ITAS2010) were calculated retrospectively.
Results: A total of 11 children (64% female) with age at diagnosis of 11.8 (1.3 to 17) years were identified over a
23-year period. The median time to diagnosis was 17 (0 to 132) months. The most common clinical features at
presentation were arterial hypertension (72.7%), systemic features (36%) and cardiovascular (45%), neurological (36%),
pulmonary (27%), skin (9%), renal (9%) and gastrointestinal (9%) involvement. At presentation, PVAS was 5/63 (1 to 13);
DEI.Tak was 7/81 (2 to 12) and ITAS2010 was 9/57 (6 to 20). Treatment included corticosteroids (81.8%), combined with
methotrexate in most cases (72.7%). Cyclophosphamide (36.4%) and biologic agents (45.5%) were reserved for severe
and/or refractory cases. PVDI at latest follow-up was 5.5/72 (3 to 15). Mortality was 27%. Young age at disease onset
(<5 years old) and permanent PVDI scores ≥3 were significantly associated with mortality risk (P=0. 02 4) .
Conclusion: TA is a rare and potentially life-threatening large-vessel vasculitis. Improved awareness of TA is essential to
secure a timely diagnosis. Although the evidence base for the treatment of TA in children is weak, we found that it is
essential to treat it aggressively because our data emphasise that the mortality and morbidity in the paediatric
population remains high.
Introduction
Takayasu arteritis (TA) is an idiopathic large-vessel vascu-
litis (LVV) affecting the aorta and its major branches [1].
TA has a worldwide distribution, with a reported inci-
dence of 1.2 to 2.6 per 1 million per year in Caucasians
and a 100-fold higher incidence in East Asians [2-4].
Although the disease rarely affects children, it does occur,
even in infants [5-7]. Diagnostic delay is unfortunately
common [5], sometimes occurring years after the acute
onset of TA. Untreated TA commonly leads to cardio-
vascular injuries, such as aneurysm formation, concentric
arterial wall fibrosis and thrombotic complications [8,9].
Because large artery biopsies are usually infeasible and
laboratory investigations are neither sensitive nor specific,
the diagnosis of TA is based on clinical features, including
a history compatible with systemic inflammation (with
or without documentation of acute-phase response)
and angiographic features compatible with LVV [7,8].
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tomography angiography (CTA) or magnetic resonance
angiography (MRA) [10,11]. Other imaging modalities,
such as
18F-fluorodeoxyglucose (
18F-FDG) positron emis-
sion tomography-computed tomography (PET-CT) [12]
or, more recently,
18F-FDG PET magnetic resonance
imaging (
18F-FDG-PET-MRI) [10] can provide important
adjunctive information, although their sensitivity and spe-
cificity for TA disease activity are not well defined, particu-
larly in children.
Notably, there is a lack of high-quality evidence on
which to base treatment recommendations in adults,
and there is even less in children [13]. Hence, there is an
ongoing need to describe the limited paediatric TA ex-
perience available because formal clinical trials are un-
likely to come to fruition within the next decade, if ever.
The majority of currently published studies describe
childhood-onset disease in countries where TA is most
prevalent [7,11,14]. The clinical phenotype and disease
burden in the UK paediatric population are currently
not well defined, even though case reports have raised
concerns that TA may have the worst long-term prog-
nosis of all the paediatric vasculitides in the United
Kingdom [5,8,9]. To address this issue, we established
the following aims in the present study: (1) to describe
the presenting clinical, histopathological and radiological
findings; (2) to explore the utility of currently available
disease activity and damage instruments for evaluating
TA; (3) to describe the treatments used; and (4) to
describe outcomes for children with TA in a UK paediat-
ric rheumatology tertiary referral centre.
Methods
Patient identification and ethical approval
We identified, by searching clinical and radiological
databases, all the patients with a clinical diagnosis of TA
seen at Great Ormond Street Hospital (GOSH) in London
between January 1990 and May 2013. One patient was
referred to GOSH from Sheffield Children’s Hospital; the
team there (AM and MO) continued to provide shared care
for this child. Case notes were reviewed retrospectively, and
patients fulfilling the following classification criteria of
the European League against Rheumatism, the Paediatric
Rheumatology European Society and the Paediatric
Rheumatology International Trials Organisation for child-
hood TA were included in the study [15]: angiographic ab-
normalities of the aorta or its main branches (mandatory
criterion) plus at least one of the following four features—
(1) decreased peripheral artery pulse(s) and/or claudication
of extremities; (2) blood pressure difference >10 mmHg;
(3) bruits over the aorta and/or its major branches; and/or
(4) hypertension (related to childhood normative data)
[15]. Ethical approval was granted by the Institute of Child
Health/GOSH Ethics Committee for a retrospective case
notes review, and no individual patient consent was there-
fore required.
Data gathered
Data recorded at diagnosis included sex, age, ethnicity,
blood pressure and organ involvement. Disease activity
was assessed retrospectively using a number of tools: the
Paediatric Vasculitis Activity Score (PVAS) [16], the
Disease Extent Index-Takayasu (DEI.Tak) [17] and the
Indian Takayasu Arteritis Activity Score (ITAS2010)
(Additional files 1, 2, 3, 4 and 5) [18]. The PVAS is a val-
idated disease activity tool specific to paediatric vascu-
litis and is the only tool currently used as an outcome
measure in paediatric vasculitis clinical trials. Despite
that, data related to PVAS and LVV are limited. The
ITAS2010 and DEI.Tak are TA-specific disease activity
tools. The DEI.Tak was designed to record disease ex-
tent, including both activity and damage. The ITAS2010
provides a quantitative score of new active disease. The
use of these two TA-specific tools has been validated in
large adult studies for interrater reliability, convergence
with Birmingham Vasculitis Activity Score (BVAS),
correlation with the Physician’s Global Assessment
and erythrocyte sedimentation rate (ESR) and serum
C-reactive protein (CRP), ability to discriminate between
active and inactive disease state at first visit, and sensi-
tivity to change. Neither of the two TA-specific tools is
currently used in routine paediatric practice, however.
Therefore, the purpose of using all three in the present
study was to compare and contrast them to provide
insight into their relative clinical utility and to inform
future studies regarding their refinement. ESR, serum
CRP, cardiac enzymes (troponin where available), levels of
antineutrophil cytoplasmic antibodies (ANCA) and anti-
nuclear antibodies (ANA), and histopathological findings
were reviewed. Other investigation results recorded,
when available, included electrocardiograms (ECGs),
echocardiograms, plain radiographs, ultrasonograms, CTA
scans, MRA and MRI scans, digital subtraction angiography
(DSA) scans,
18F-FDG-PET scans and dual-energy x-ray
absorptiometry (DEXA) scans. The time to diagnosis and
medical and surgical treatments were also recorded.
Outcome measures included changes in acute-phase reac-
tants, PVAS, ITAS2010, DEI.Tak, z-scores for height and
weight at latest follow-up, cause of death and contributing
factors, disease and treatment-related adverse events, and
frequency of osteopenia, defined as a z-score for bone
density more than 2 standard deviations below the mean for
age identified with a DEXA scan. The Paediatric Vasculitis
Damage Index (PVDI) [19] was calculated retrospectively.
PVDI is based on a modified version of the adult Vasculitis
Damage Index tool [19]. Despite the fact that the paedi-
atric version is not yet validated, we explored its utility
in the present study because it provides a systematic
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text of vasculitis.
Statistical analysis
Continuous variables were summarized as median and
range. Categorical variables are presented as percentages
and frequencies. Parameters between groups were com-
pared using Fisher’s exact test. Wilcoxon matched-pairs
signed-rank tests were used for comparisons before and
after biologic therapy. Correlations between disease activity
tools were assessed using Spearman’s correlation coeffi-
cient. A P-value (two-sided) <0.05 was considered signifi-
cant. Statistical analyses were performed using IBM SPSS
version 18 software (IBM, Armonk, NY, USA). Growth
standard deviation scores (z-scores) were calculated based
on UK normative data using a free downloadable Micro-
soft Excel add-on [20].
Results
Demographics and clinical manifestations at presentation
A total of 11 children (64% female, n =7) aged 11.8 (1.3
to 17.0) years who fulfilled the classification criteria for
TA were identified (Table 1). Eight (72%) of eleven were
Caucasian, two (18%) were Asian and one (9%) was
Afro-Caribbean. The median interval from first symp-
tom onset to diagnosis was 17 (0 to 132) months. PVAS
at presentation was 5/63 (1 to 13); DEI.Tak was 7/81;
and ITAS2010 was 9/57 (6 to 20). The classification of
TA was based on the presence of angiographic abnor-
malities of the aorta or its main branches (present in all
11 patients), plus at least one of the following four fea-
tures: decreased peripheral artery pulse(s) (3/11, 27%),
blood pressure difference >10 mmHg (3/11, 27%), bruits
over the aorta and/or its major branches (6/11, 54%)
and/or hypertension related to childhood normative data
(8/11, 72%).
The main presenting clinical features are shown in
Table 2. Arterial hypertension was the commonest pre-
senting feature.
Established cardiac and/or large arterial injury was com-
mon at presentation. A total of 5 (45%) of 11 patients
presented with bruits over the aorta and/or its major
branches. Three patients (27%) had cardiomyopathy. Loss
of peripheral pulses was documented in two patients (18%).
Ischaemic cardiac pain was confirmed on ECGs and with
elevated troponin in two patients (18%). Lower-limb claudi-
cation was present in one patient (9%), pericarditis in one
p a t i e n t( 9 % )a n dv a l v u l a rh e a r t disease in one patient (9%).
Table 1 Time to diagnosis, disease activity measures and outcomes in a cohort of 11 patients with childhood Takayasu
arteritis
a
Patient
number
Time to
diagnosis (mo)
PVAS/ITAS2010/DEI.
Tak at diagnosis
Surgical/endovascular intervention(s) Follow-up (mo) Status at last
follow-up
1 42 1/6/5 Repair of LV aneurysm (twice), ascending aorta aneurysm
repair, AMPLATZER Septal Occluder device (AGA Medical,
Golden Valley, MN, USA) insertion, stent insertion within
ascending aorta, coil embolisation of right CA aneurysm
11 Remission on
treatment
2 2 10/15/12 Mitral valvuloplasty and aortic root replacement, subsequent
LIMA bypass graft for stenotic left CA
32 Remission on
treatment
3 4 5/16/7 – 16 Relapse on
treatment
4 7 10/15/9 – 36 Remission on
treatment
5 132 2/6/2 – 24 Remission off
treatment
6 0 2/10/6 Angioplasty of both renal arteries, SMA and external iliac
arteries; coil embolisation of a cerebral artery aneurysm
168 Deceased
7 120 5/9/7 – 11 Deceased
8 17 3/8/8 – 6 Remission on
treatment
9 18 1/6/5 – 6 Remission off
treatment
10 0 3/10/5 Angioplasty of the renal arteries (twice) 26 Remission on
treatment
11 60 12/9/12 Angioplasty of abdominal aorta; required subsequent
surgical repair
14 Deceased
aCA, Coronary artery; DEI.Tak, Disease Extent Index-Takayasu; ITAS2010, Indian Takayasu Arteritis Activity Score; LIMA, Left internal mammary artery; LV, Left ventricle;
PVAS, Paediatric Vasculitis Activity Score; SMA, Superior mesenteric artery. Total possible scores range from 0 to 63 for PVAS, from 0 to 57 for ITAS2010 and from 0 to 81
for DEI.Tak (0–81). Higher scores reflect higher disease activity for all tools [16-18].
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presentation. Patient 1 presented with a giant aneurysm
of the left ventricle (LV). The aneurysm was considered
traumatic because his symptoms were preceded by dir-
ect (albeit mild) trauma to his chest, and he underwent
surgical repair. Over the course of the next 4 years, he
had a number of surgical procedures, including surgery
for LV aneurysm recurrence. Histology of the LV and
aortic wall tissue indicated the presence of inflammatory
cells and laminated thrombus compatible with a false
aneurysm, and the aortic wall intima showed necrosis
with surface fibrinous exudate. On the basis of these car-
diac histological findings, he was eventually diagnosed
with TA. Patient 2 presented in infancy, when she was
admitted acutely to the cardiac intensive care unit with
pulmonary oedema secondary to severe acute aortic and
mitral valve regurgitation; the full details of this case are
published elsewhere [5].
Laboratory parameters
At diagnosis for all 11 patients, the median ESR was 72 (12
to 108) mm/hr and CRP was 53 (0 to 237) mg/L. ANCA
were negative for four patients tested. ANA were modestly
positive (≤1:320) in two of six patients tested. For two
(18%) of eleven patients who presented with ischaemic
cardiac pain, there was an increase in troponin levels
8.7 (range 5.40-12; normal levels <0.04 microgram/L).
Histology
Histology results were available for five (45%) of eleven
patients. Four were obtained at diagnosis: mitral valve
(n =1), left ventricle myocardium (n =1), pericardium
(n =1) and intestinal biopsy (n =1). One was obtained
from a postmortem autopsy for one of the deceased pa-
tients (renal and cardiac tissue; patient 7). Histology
showed florid vasculitis in three of the five patients, fi-
brous intimal thickening in four patients (periadventitial
and adventitial), calcification in one, small vessel
Table 2 Presenting clinical features in a UK-based cohort
of 11 patients with childhood Takayasu arteritis
a
Presenting features Number of patients
with features (%)
Sex
Female:male 7 (64%):4 (36%)
Ethnicity
Caucasian 8 (73%)
Asian 2 (18%)
Afro-Caribbean 1 (9%)
Systemic features 4 (36%)
Fever 4 (36%)
Weight loss >5% of body weight 4 (36%)
Myalgia 1 (9%)
Arthralgia or arthritis 1 (9%)
Skin involvement 1 (9%)
Livedo reticularis 0 (0%)
Purpura 1 (9%)
Other skin vasculitis (vasculitis different from
previous, such as subcutaneous oedema,
Raynaud’s phenomenon)
1 (9%)
Mucous membranes/eyes 1 (9%)
Red eye conjunctivitis 1 (9%)
Arterial hypertension >95% percentile for age 8 (73%)
Renal involvement 1 (9%)
Proteinuria (>0.3 g/24 hr or >20 mmol/mg
creatinine)
1 (9%)
Haematuria (≥5 rbc/hpf or rbc casts) 1 (9%)
Rise in creatinine >10% or creatinine clearance
(GFR) decrease >25%
1 (9%)
Neurological involvement 4 (36%)
Headache 4 (36%)
Organic confusion/cognitive dysfunction 1 (9%)
Meningitis/encephalitis 0 (0%)
Seizures (not hypertensive) 2 (18%)
Stroke 2 (18%)
Gastrointestinal involvement 1 (9%)
Abdominal pain 1 (9%)
Peritonitis 0 (0%)
Blood in the stools or bloody diarrhoea 0 (0%)
Bowel ischaemia/perforation 0 (0%)
Cardiovascular involvement 5 (45%)
Loss of pulses 2 (18%)
Bruits over accessible arteries 5 (45%)
Blood pressure discrepancy 2 (18%)
Claudication of extremities 1 (9%)
Ischaemic cardiac pain 2 (18%)
Cardiomyopathy 3 (27%)
Table 2 Presenting clinical features in a UK-based cohort
of 11 patients with childhood Takayasu arteritis
a
(Continued)
Congestive cardiac failure 2 (18%)
Valvular heart disease 1 (9%)
Pericarditis 1 (9%)
Pulmonary involvement 3 (27%)
Wheeze or expiratory dyspnoea 3 (27%)
Pleural effusion 3 (27%)
Infiltrate 2 (18%)
Massive haemoptysis/alveolar haemorrhage 0 (0%)
Respiratory failure 3 (27%)
aGFR, Glomerular filtration rate; hpf, High-powered field; rbc, Red blood cells.
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sation in two. Intestinal biopsy was normal in the one
single patient that had an intestinal biopsy.
Imaging studies
MRI with gadolinium contrast enhancement and/or MRA
imaging studies (performed in all patients at diagnosis) re-
vealed abnormalities in all patients as follows: arterial nar-
rowing and stenosis (10/11; 90%), arterial dilatation or
aneurysm formation (7/11; 63%), arterial wall thickening
(9/11; 81%) and collateral vessels or other calibre varia-
tions (10/11; 90%). A total of eight (73%) of eleven patients
had positive gadolinium contrast arterial wall enhance-
ment, consistent with active LVV at the time the study
was undertaken. CTA was performed in six patients,
which revealed pseudoaneurysms and/or aneurysms (4/6),
reduced and/or absent blood flow (3/6), narrowing and/
or stenosis (4/6), arterial calcifications (2/6) and occlusion
(1/6). DSA was performed in four (36%) of eleven patients
and showed stenosis of thoracic and abdominal aortas in
two patients, collaterals in two, stenosis of renal arteries in
one and cerebral aneurysms in one.
18F-FDG-PET was
performed in four (36%) of eleven patients and revealed
avid uptake, mostly in the ascending aorta, in two of
four studies.
The distribution of involved arteries according to the
angiographic classification of TA [21] showed that the
most common type of vessel involvement was type V
(Table 3). The most common type of lesion was stenosis,
which was present in nine (81%) of eleven patients,
followed by aneurysms in five (45%), dilatation in three
(27%) and occlusion in two (18%).
Treatment
The general therapeutic approach in our cohort was that of
induction of remission (high-dose corticosteroid combined
with another immunosuppressant), followed by main-
tenance of remission therapy (lower-dose corticosteroid
combined with a maintenance immunosuppressive agent,
usually methotrexate (MTX)) or institution of second-line
therapy for failed induction. The medical treatments re-
ceived by the patients are summarized in Additional file 6:
Table S1.
Corticosteroids
Nine (81%) of eleven patients received corticosteroids as
induction therapy. Five of these nine patients received
prednisolone at 1 or 2 mg/kg/day; the remaining four
received intravenous methylprednisolone 30 mg/kg for
3 days and were then switched to oral prednisolone 1 or
2 mg/kg/day. Two patients (patients 5 and 7) did not re-
ceive corticosteroids (or any other immunosuppressive
agent), because the diagnosis of TA was made in the late
stenotic phase of the disease (132 and 123 months, re-
spectively, after the acute onset of the disease), and clin-
ically and/or radiologically these patients had absence of
disease activity.
Adjunctive immunosuppressive therapy
First-line therapies were as follows: Four (36%) of eleven
patients received weekly subcutaneous MTX combined
with corticosteroids three (27%) received cyclophospha-
mide at induction, two (18%) received intravenous im-
munoglobulin (2 g/kg) and one (9%) received azathioprine
(2 to 3.7 mg/kg/day).
Regarding second-line therapy, five (45%) of eleven pa-
tients were switched to MTX at a median of 8 (5 to 132)
months from diagnosis. Overall, there was evidence of
ongoing disease activity at that time as indicated by all
three disease activity measures: PVAS of 7/63 (2 to 11),
ITAS2010 of 11/57 (5 to 14/), DEI.Tak of 8/81 (8 to 15/81).
At that time point, median ESR was 11 (2 to 56) mm/hr
and median CRP was 9.5 (1 to 20) mg/L. The median dose
of oral prednisolone for these patients was 0.3 (0.2 to 0.75)
mg/kg/day. Patient 11, who had been on MTX for
7 months as a first-line therapy, was switched to cyclo-
p h o s p h a m i d eb e c a u s es h eh a dp r o g r e s s i v ed i s e a s ed e -
tected by MRA.
Biologic therapies
Biologic therapy was initiated for 6 (54%) of 11 patients
at 11 (4 to 156) months from diagnosis. The median
ESR was 63 (3 to 115) mm/hr, and the median CRP was
37 (3 to 140) mg/L. Anti–tumour necrosis factor alpha
(anti-TNFα) therapy was the first class of biologic agent
chosen in all six cases. Three patients received adalimu-
mab (24 mg/m
2 fortnightly if body weight was <30 kg,
40 mg fortnightly if >30 kg) as the first biologic. Three
patients received infliximab (6 mg/kg intravenously
monthly) as the first biologic, including patient 2, who
was later converted to adalimumab because of difficul-
ties with venous access. Patient 3 was switched from
Table 3 Distribution of involved vessels according to the
new angiographic classification of Takayasu arteritis in a
cohort of 11 children in a UK-based centre
a
Type Types of affected vessels Number of
patients (N= 11)
I Branches from aortic arch only 0
IIa Ascending aorta, aortic arch and its branches 1 C+
IIb Ascending aorta, aortic arch and its branches,
thoracic descending aorta
0
III Thoracic descending aorta, abdominal
aorta and/or renal arteries
1P +
IV Abdominal aorta and/or renal arteries 2
V Combined features of types IIb and IV 7 (1/7 C+)
aAccording to this classification system [21], involvement of the coronary or
pulmonary arteries is designated as C(+) or P(+), respectively.
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diagnosis because he developed severe myalgia and
arthralgia with raised inflammatory markers. The me-
dian dose of prednisolone at time of biologic therapy
initiation was 0.2 (0.1 to 2) mg/kg/day, and, at a median
of 2.5 (2 to 28 months) of biologic therapy, it was 0 (0 to
0.6) mg/kg/day (P =0.41). In addition, in response to this
biologic therapy, PVAS changed from 9.5/63 (4 to 24) to
0/63 (0 to 21) (P=0.312), ITAS2010 changed from 6/57
(4 to 18) to 0/57 (0 to 18) (P =0.104) and DEI.Tak chan-
ged from 3/81 (1 to 20) to 0/82 (0 to 20) (P =0.187). Of
note, in patient 3, the PVAS score was 0/63 at the time of
initiation of biologic therapy, indicating absence of clin-
ical disease activity; however, the ITAS2010 and DEI.Tak
scores were 4/57 and 2/81, respectively. Regarding pa-
tient 3, following an initially promising response to toci-
lizumab, the disease relapsed 12 months later, and, at the
time of this writing, this patient was receiving rituximab.
Other medical therapy
Additional file 6: Table S1 (available online) summarizes
the adjunctive medical therapy received. Seven (63%) of
eleven patients required a median of three (range, from
two to six) antihypertensive medications, five received
antiplatelet doses of aspirin and two received anticoagu-
lation (warfarin after initial heparinisation). Patient 11
required treatment with sildenafil and epoprostenol infu-
sion for pulmonary arterial hypertension that developed
4 months following diagnosis.
Surgical and endovascular management
Five patients required surgical and/or endovascular
treatment. These procedures are summarized in Table 1.
Outcomes
The median length of follow-up was 16 (6 to 168)
months. At the last follow-up, PVAS was 0/63 (0 to 21),
ITAS2010 was 0/57 (0 to 18) and DEI.Tak was 0/81
(0 to 20). ESR was 5 (2 to 20) mm/hr, and CRP was
5 (range 1 to 12) mg/L. Seven of eleven patients were in
remission at latest follow-up, as indicated by normal
CRP and ESR values and a PVAS of 0 on two consecu-
tive measurements 1 month apart [16]. The following
corticosteroid-associated side effects were documented
in 72.7% (8/11) of the patients: Cushing’s syndrome (5/8;
62%), osteoporosis (2/8; 25%), skeletal fracture (1/8;
12.5%) and hip avascular necrosis (1/8; 12.5%).
The median z-score for height at diagnosis was −0.10
(−1.39 to 3.79), and at the last follow-up it was −0.89
(−5.6 to 1.58) (P =0.019). The median z-score for weight
at diagnosis was +1.13 (−0.96 to 3.46), and it was +0.47
(−9.21 to 2.57) at the last follow-up (P= 0.019).
Two patients had pancytopenia, which was related to
treatment with MTX and cyclophosphamide, respectively.
Both recovered with cessation of therapy. Patient 11 devel-
oped Candida and Pseudomonas sepsis whilst in intensive
care for multiorgan failure.
The median PVDI at latest follow-up was 5.5/72 (3 to
15). When the items that had been present for more than
3 months at one time but had resolved at latest follow-up
[19] were removed, the PVDI changed to 3/72 (0 to 10).
Three of eleven patients died during follow-up (27%
mortality). Patient 7 presented with acute cardiomyop-
athy, and no clear diagnosis was made at initial presenta-
tion. Approximately 6 years later, the diagnosis of TA
was made based on the loss of peripheral pulses and
lower-limb claudication. Patient 7 did not receive any
immunosuppressive treatment, as he was considered to
be in the late stenotic phase of the disease. Four years
after receiving his diagnosis, he collapsed suddenly and
died. The postmortem examination revealed severe LV
hypertrophy and 70% occlusion of the coronary arteries.
His abdominal aorta was narrowed and had a patchy
and sparse chronic inflammatory cell infiltrate and evi-
dence of active inflammation within the vasa vasorum of
the distal aorta. His final PVDI was 5/72.
Patient 6 was diagnosed with TA at screening after her
sister had died as a result of TA [9]. Patient 6 received
treatment with corticosteroids, azathioprine, MTX and
adalimumab. She accrued significant damage over time.
Her final PVDI score was 10/72. She died suddenly as a
result of acute aortic rupture 15 years following diagnosis.
Patient 11 was diagnosed with coarctation of the aorta
during her first 5 years of life and had undergone surgi-
cal repair with patch augmentation. She was followed up
for severe arterial hypertension for the next 3 years. At 3
years after her diagnosis, she presented with acute re-
spiratory failure, pericarditis, no palpable pulses on the
lower limbs due to critical stenosis of the whole aorta
and the main branches, anuria and hypertension. She
died as a result of progressive multiorgan failure, despite
receiving escalating immunosuppression (high-dose in-
travenous methylprednisolone, MTX, cyclophosphamide,
infliximab). Her final PVDI was 12/72.
Correlations between Takayasu arteritis vasculitis disease
activity tools
Figure 1 shows the correlations among the various TA dis-
ease assessment instruments at the time of diagnosis and
follow-up. PVAS correlated strongly with both ITAS2010
(r=0. 66 ; P=0. 03 0) an d DEI .T ak (r=0. 86 ; P=0.0012) at
diagnosis and latest follow-up (ITAS2010: r=0.98, P=
0.0001; DEI.Tak: r=1 ,P=0.0001).
Factors associated with mortality
Age at disease onset ≤5 years was significantly associ-
ated with mortality (P =0.024). Permanent damage
items on PVDI scoring at latest follow-up ≥3/72 were
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There was no statistical association between mortality
and time to diagnosis >12 months (P =0. 54 5) , car diac
involvement (P =0.18), endovascular procedures within
12 months of diagnosis (P =0 . 5 4 5 )o rn e e df o rb i o l o g i c
therapy (P =1) (Additional file 7: Table S2).
Discussion
In our present retrospective study, we report the largest
UK cohort so far of paediatric patients with TA. This
study is the first to systematically apply three different
vasculitis disease activity scores and to explore damage
accrual using the PVDI. We observed a significant delay
in diagnosis (up to 132 months) due to the insidious and
non-specific presentation of TA. The burden of disease
and its therapy was high, as depicted by PVDI scores at
latest follow-up. Biologic therapies were used in 54% of
patients for therapy-resistant disease. Mortality was high
at 27%. Disease onset before 5 years of age and persist-
ent damage items providing PVDI scores ≥3 were signifi-
cantly associated with mortality.
Similarly to other case series, the most common pre-
senting feature of TA in our study was arterial hyperten-
sion (70%), but notably in the absence of other systemic
symptoms, which may partly explain the diagnostic delay
[6-8,14]. We report a higher frequency of cardiac and
neurological involvement in our sample compared with
other published paediatric TA cohorts, perhaps reflect-
ing the severity of the cases referred to our tertiary care
centre. The frequency of cutaneous and musculoskeletal
symptoms were similar to other reports, however [6-8,14].
We emphasize that severe cardiac involvement can be the
first presenting feature of LVV in children (3 of 11 patients
in our study).
Histology for the majority of our cases revealed bland
lymphocytic inflammation with some neovascularisation,
but absence of granulomas, in contrast to histological
studies of adult-onset TA, where granulomas are often a
major feature [22]. Because mononuclear infiltration of
the adventitia with perivascular cuffing of the vasa
vasorum is common in the early phase of TA [22,23], we
suggest that one reason why granulomas may not be so
conspicuous in children is that these patients are likely
to have had shorter disease duration at the time of tissue
sampling.
Assessment of disease activity in TA remains challen-
ging, particularly in children [8]. Acute-phase reactants
lack sufficient sensitivity to be clinically reliable; most
clinical manifestations are non-specific, and vascular
injury progresses insidiously [8]. Active vasculitis may
still be present, even in the absence of an acute-phase
response and with negative
18F-FDG PET-CT scans as in
patient 7, in whom autopsy results demonstrated
chronic active LVV. On the basis of our experiences and
those reported by others [10], we provide an approach
to the use of imaging for the diagnosis and monitoring
of TA in paediatric patients (Figure 2). In particular,
MRI techniques coregistered with PET have the poten-
tial to improve evaluation of TA, both at diagnosis and
during follow-up. The role of circulating biomarkers
such as pentaxin 3 (PTX3) level is currently unclear
[24], but PTX3 could have a role if validated in a clinical
context.
Two specific tools to assess TA disease activity and ex-
tent have been validated in adults: ITAS2010 and DEI.
Tak [17,18]. These tools were derived from the BVAS,
but with particular emphasis on cardiovascular manifes-
tations because these predominate in TA. Although they
are not validated in children, we explored their utility in
comparison with the PVAS, the only validated vasculitis
activity score for children. Perhaps unsurprisingly, activ-
ity scores using both TA-specific tools were consistently
higher than those with PVAS, as the former allow more
detailed assessment of the extent of vascular involve-
ment. We note, however, the strong correlation of mea-
surements between the PVAS versus ITAS2010 and DEI.
Tak tools at both diagnosis and follow-up, suggesting that,
overall, all three tools consistently reflect TA disease
Figure 1 Correlations between Takayasu arteritis disease activity measure tools. (A) Correlations at time of diagnosis. (B) Correlations at
time of latest follow-up. DEI.Tak, Disease Extent Index-Takayasu; ITAS2010, Indian Takayasu Arteritis Activity Score; PVAS, Paediatric Vasculitis
Activity Score. Total possible scores: PVAS: 0 to 63, ITAS2010: 0 to 57 and DEI.Tak: 0 to 81. Higher scores reflect higher disease activity for all
tools [16-18].
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modifications for age-specific items such as body weight
and arterial hypertension, as well as prospective validation
in children with TA, is now warranted. In addition, using
standard definitions of remission employed in clinical tri-
als for other vasculitides, a total of 7 of 11 patients fulfilled
remission criteria at their latest follow-up examination.
We acknowledge, however, that grumbling disease activity
may not be sufficiently captured by these clinical indices.
Further studies designed to refine and validate reliable def-
initions of disease remission and response to therapy in
TA are now needed.
We also explored the utility of the prototypic PVDI
[19] for the first time in an attempt to systematically as-
sess damage accrual. All patients scored high for items
related to cardiovascular morbidity, and 8 of 11 scored
positively for treatment-related morbidity items. Not-
ably, only permanent damage items detected using PVDI
were associated with mortality.
Corticosteroids combined with MTX or cyclophospha-
mide were the standard induction therapy for our pa-
tients. More than one-half (54%) required addition of
biologic therapy (within the latter 10 years of the study,
when these treatments became available) because of a
severe and refractory disease course. In addition to anti-
TNFα agents, promising results have been reported with
anti-interleukin-6 therapy (tocilizumab) for adults with
TA [25-27]. Tocilizumab was used for one of our pa-
tients, who went on to receive rituximab for inadequate
disease control. There has never been a controlled trial for
the treatment of TA. Rare disease trial designs that have
recently been adapted for other rare childhood vasculitides
(for example, the open-label randomised controlled trial
of mycophenolate mofetil versus cyclophosphamide for
the induction of remission of childhood polyarteritis
nodosa (ISRCTN 75434563)) should also be considered
for children withTA [28].
We report a mortality rate of 27%, which is in line
with mortality rates reported by others (ranging from
16% to 40%) [6,7,14]. Disease mortality was related to
younger age at presentation (P= 0.024). This finding is
unsurprising, given that these children had a prolonged,
severe disease course and extensive stenotic disease well
before adolescence. Whether these patients represent a
distinct group of early-onset severe disease due to an as
yet undefined genetic disorder remains to be established
[9], and this is an area of ongoing study by our group.
Our study is limited by all the confounding factors as-
sociated with any retrospective case series. We acknow-
ledge the small sample size and lack of heterogeneity of
our cohort. There is also a possibility that referral bias
resulted in the more severe spectrum of the disease ob-
served in our patients.
Conclusions
TA in children is a rare but potentially life-threatening
condition. Improved awareness of TA is essential to
securing an early diagnosis. LVV should be considered in
Figure 2 Recommended imaging algorithm for children with Takayasu arteritis. CT, Computed tomography; CTA, Computed tomography
angiography; MRA, Magnetic resonance angiography; MRI, Magnetic resonance imaging; PET, Positron emission tomography; TA, Takayasu
arteritis; USS, Ultrasound.
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without elevated acute-phase reactants. Other clinical
features are unfortunately non-specific, but the case for
suspected TA is even stronger in a patient with hyper-
tension in the presence of fever, weight loss, headaches,
arthralgia, fatigue and/or bruits. In the future, use of the
currently available clinical scores explored herein may
be beneficial for monitoring response to therapy.
Undoubtedly, however, imaging is particularly important
for the diagnosis and monitoring of LVV (Figure 2). Al-
though the evidence base for the treatment of TA in
children is weak, it is essential to treat TA aggressively
as soon as the diagnosis is secured to reduce mortality
and morbidity.
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